COSMO PHARMACEUTICALS ANNOUNCES 2021 PRELIMINARY RESULTS BEATING GUIDANCE, RETURN TO DIVIDEND DISTRIBUTION AND 2022 GUIDANCE
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced its preliminary unaudited results for 2021.
- Total revenues of €65.1m vs guidance €60m – €64m
- Operating profit of €7m – €10m vs guidance of €3m – €5m
- Profit before taxes of €20m – €23m vs guidance of €4m – €6m
These results take into account the share of Cassiopea’s profit for the year 2021, following the licensing of Winlevi® to Sun Pharmaceuticals.
In light of these very encouraging results and of the 2022 outlook, Cosmo’s Board of Directors has resolved to propose at the upcoming AGM on May 27, 2022, the distribution of a cash dividend of €0.95 (equivalent to approx. CHF1.0) per share to its shareholders.